{"filing":{"accession_number":"0001356576-26-000035","cik":"0001356576","ticker":"SUPN","company_name":"SUPERNUS PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"supn-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657626000035/supn-20260803.htm"},"events":[{"id":23005,"run_id":20825,"accession_number":"0001356576-26-000035","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The Item 2.02 disclosure centers on Supernus's second quarter 2026 financial results, with total revenues of $219.1 million (32% increase YoY) and updated full-year 2026 guidance. The press release (Exhibit 99.1) provides detailed revenue breakdowns by product, operating results, and cash position. While the filing also mentions the pending merger with Indivior, the primary substance of Item 2.02 is the earnings announcement and financial guidance update, which is the core material event disclosed in this section.","company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23140,"accession_number":"0001356576-26-000035","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 2.02 disclosure centers on Supernus's second quarter 2026 financial results, with total revenues of $219.1 million (32% increase YoY) and updated full-year 2026 guidance. The press release (Exhibit 99.1) provides detailed revenue breakdowns by product, operating results, and cash position. While the filing also mentions the pending merger with Indivior, the primary substance of Item 2.02 is the earnings announcement and financial guidance update, which is the core material event disclosed in this section.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T10:47:38.222182+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23140,"accession_number":"0001356576-26-000035","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 2.02 disclosure centers on Supernus's second quarter 2026 financial results, with total revenues of $219.1 million (32% increase YoY) and updated full-year 2026 guidance. The press release (Exhibit 99.1) provides detailed revenue breakdowns by product, operating results, and cash position. While the filing also mentions the pending merger with Indivior, the primary substance of Item 2.02 is the earnings announcement and financial guidance update, which is the core material event disclosed in this section.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T10:47:38.222182+00:00","company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","filing_date":"2026-08-03"}]}